The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.

Li, Pengyun; Li, Bingkun; Yang, Ning; Xu, Tingting; Zheng, Zhibing

Li, Pengyun; Li, Bingkun; Yang, Ning; Xu, Tingting; Zheng, Zhibing.

Afiliação

Li P; National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Li B; National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Yang N; National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Xu T; National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Zheng Z; National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, China.

Expert Opin Ther Pat ; 33(7-8): 477-492, 2023.

Article em En | MEDLINE | ID: mdl-37873645

Assuntos

Carcinoma Pulmonar de Células não Pequenas; Neoplasias Pulmonares; Humanos; Quimera de Direcionamento de Proteólise; Patentes como Assunto; Receptores ErbB

Palavras-chave

EGFR; Non-small cell lung cancer; PROTACs; mutation; protein degradation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google